Mode
Text Size
Log in / Sign up

Impact of Targeted Left Ventricular Lead Placement on Heart Failure OutcomesTrial shows specific lead placement does not improve heart failure outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Targeting the latest electrically activated site for LV lead placement does not improve primary outcomes in heart failure.

This multicenter randomized controlled trial investigated the clinical efficacy of a specific technique for left ventricular (LV) lead placement in patients with heart failure and wide QRS complexes. The study aimed to determine if placing the lead at the site of the latest electrical activation within the coronary sinus branches provided superior outcomes compared to traditional placement in a posterolateral non-apical branch. The study enrolled over 1,000 patients across five Danish university centers, providing a robust sample size for evaluating this specific procedural variation.

The primary endpoint was a composite of time to death or the first unplanned heart failure hospitalization. This is a critical metric for assessing the long-term stability and efficacy of cardiac resynchronization therapy. The study followed patients for a median of 45.8 months, allowing for a substantial observation period to capture significant clinical events. The methodology was designed to isolate the impact of the specific anatomical placement site on these primary clinical outcomes.

Results indicated that the intervention group, which received lead placement at the site of latest electrical activation, showed a 28% event rate compared to 26% in the control group. The hazard ratio was 1.10 with a 95% confidence interval of 0.86-1.39, resulting in a p-value of 0.45. These findings suggest that targeting the specific electrical activation site does not significantly reduce the risk of death or unplanned hospitalization when compared to the standard posterolateral placement. Secondary outcomes included the assessment of overall complication risks and specific lead-related complications. While the intervention group showed a slightly higher rate of overall complications (14% vs 13%), the difference did not reach statistical significance. However, it was noted that lead-related complications were more frequent in the intervention group. This suggests that while the technique is feasible, it may carry a marginally higher risk of technical complications during the implantation procedure. From a technical standpoint, the intervention group showed a mean of 9 milliseconds later in electrical activation at the lead site (95% CI 5-13). While this confirms the successful identification of the target site during the procedure, it did not translate into a measurable improvement in the primary clinical endpoints. The data suggests that the physiological benefit of the specific site selection is not sufficient to overcome the baseline risks associated with heart failure management. Clinicians can conclude that while the technique of targeting the latest electrically activated site is technically feasible, it does not offer a superior clinical outcome over conventional placement in the posterolateral non-apical branch. The study highlights that for patients with wide QRS and heart failure, standard placement remains a reliable and comparable method. The findings emphasize that the primary goal of reducing mortality and hospitalization is not significantly altered by this specific anatomical refinement in the coronary sinus branches.

How this fits prior evidence

How this fits prior evidence This study addresses a gap in the management of heart failure with wide QRS by evaluating specific lead placement techniques. While previous coverage has addressed other aspects of heart failure, such as the consideration of dystrophinopathy in adolescent males with nonischemic cardiomyopathy and heart failure, this trial specifically addresses the technical nuances of cardiac pacing. The finding confirms that the specialized placement at the latest electrically activated site does not improve the composite endpoint of death or unplanned hospitalization compared to standard placement.

Living with heart failure is a significant challenge for many people. For those with specific types of heart rhythm issues, doctors often use a device with leads placed in the heart to help manage the condition. Because the placement of these leads can be complex, medical professionals often look for the most effective techniques to improve the lives of their patients. This study aimed to see if a specific method of placing these leads could lead to better outcomes for people with heart failure.

Researchers conducted a large, multicenter study involving 1,000 patients. These patients all had heart failure and a specific electrical pattern on their heart monitors. The study was designed to compare two different ways of placing a left ventricular lead. The first group received a lead placed at the site of the latest electrical activity. The second group received a lead placed in a more traditional location. The goal was to see if the first method would reduce the number of deaths or unplanned hospital stays for heart failure.

After following the patients for a median of about 46 months, the results showed no significant difference between the two methods. In the first group, 28 percent of patients experienced the primary outcome of death or unplanned hospitalization. In the second group, 26 percent of patients experienced the same outcome. These numbers were very close, and the statistical analysis confirmed that the specific placement technique did not provide a measurable advantage in preventing hospitalizations or death.

Regarding safety, the study noted that lead-related complications were slightly more frequent in the group that received the more complex placement technique. There was one death related to the procedure in that group. While the difference in overall complications was small, it is important for doctors to weigh the complexity of a procedure against the potential benefits. In this case, the more complex method did not result in better health outcomes for the patients.

It is important to remember that this is one study focused on a specific type of heart failure and a specific placement technique. While the results are clear for this group of patients, they do not change the standard of care for everyone with heart issues. Patients should continue to work closely with their cardiology teams to determine the best treatment plan based on their individual health needs. For now, this research suggests that the traditional method of lead placement remains a reliable option for managing heart failure.

What this means for you:
A specific technique for placing heart device leads did not reduce death or hospital stays for heart failure patients.

Study Details

Study typeRct
Sample sizen = 1,001
EvidenceLevel 2
Follow-up8.0 mo
PublishedSep 2026
View Original Abstract ↓
BACKGROUND: Left ventricular lead position is a key determinant of optimal biventricular pacing for heart failure. Observational data indicate better outcomes in patients with late myocardial activation at the left ventricular lead site. We aimed to test whether targeting the left ventricular lead at site of latest electrical activation improves outcomes. METHODS: In this national, randomised, controlled, double-blinded, superiority trial we included patients from all five Danish university centres performing device implantation who had heart failure and wide QRS on guideline-directed medication, eligible for biventricular pacing. We randomly assigned (1:1) patients to either the intervention group, with left ventricular lead placement at the latest electrically activated site within the coronary sinus branches, or to control group, with left ventricular lead placement in a posterolateral non-apical branch. Primary outcome was a composite of time to death or first unplanned heart failure hospitalisation. We used block randomisation and masked patients and all study personnel (except operating room personnel) to treatment allocation. The primary outcome was a composite of time to death or first unplanned hospitalisation for heart failure. Analysis followed a modified intention-to-treat approach. Safety was assessed in all correctly assigned patients. The trial is registered at ClinicalTrials.gov (NCT03280862) and is complete. FINDINGS: From March 20, 2018, to June 3, 2024, we included 1001 patients (255 females and 746 males); 499 were randomly assigned to the intervention group and 502 to the control group. One incorrectly enrolled patient was excluded, leaving 1000 patients for the modified intention-to-treat analysis. Electrical activation at left ventricular lead was a mean of 9 milliseconds (95% CI 5-13) later in the intervention group. Follow-up was completed on Feb 27, 2026, after a median 45·8 months (IQR 28·5-65·7). The primary endpoint occurred in 139 (28%) of 499 patients in the intervention group and 128 (26%) of 501 in control group (hazard ratio 1·10 [95% CI 0·86-1·39]; p=0·45). Overall complication risk was similar between groups (71 [14%] patients in the intervention group vs 64 [13%] in the control group), but lead-related complications were more frequent in the intervention group. One procedure-related death occurred in the intervention group. INTERPRETATION: In patients with heart failure and prolonged QRS, targeted left ventricular lead placement at the site of latest electrical activation did not reduce the composite endpoint of death or unplanned hospitalisation for heart failure compared with conventional lead placement in a posterolateral, non-apical position. FUNDING: Novo Nordisk Foundation, Danish Heart Foundation, Danish Pacemaker and ICD Registry, and Independent Research Fund Denmark.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.